Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-MUC1 CAR-T in MUC1+ Advanced Solid Tumors
NCT02617134Phase 2Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Nov 2015
- Primary completion
- Nov 2017
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of anti-muc1 car-t cells in malignant glioma, colorectal carcinoma (CRC), Gastric carcinoma (GC), sponsored by PersonGen BioTherapeutics. Status: unknown.
02
Drugs
anti-muc1 car-t cells
03
Conditions
malignant gliomacolorectal carcinoma (CRC)Gastric carcinoma (GC)
Beyond the preview
Go deeper on NCT02617134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02617134.